{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T19:57:30Z","timestamp":1775159850371,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009480","name":"Friends of the Sophia Foundation","doi-asserted-by":"publisher","award":["S18-59"],"award-info":[{"award-number":["S18-59"]}],"id":[{"id":"10.13039\/501100009480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022790","name":"Sophia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["40-40300-98-07010"],"award-info":[{"award-number":["40-40300-98-07010"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OP20-04"],"award-info":[{"award-number":["W.OP20-04"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201206240040"],"award-info":[{"award-number":["201206240040"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022691","name":"National Weather Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016062","name":"Stichting Metakids","doi-asserted-by":"publisher","award":["2018-083"],"award-info":[{"award-number":["2018-083"]}],"id":[{"id":"10.13039\/100016062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jprot.2023.105037","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T14:51:58Z","timestamp":1698677518000},"page":"105037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease"],"prefix":"10.1016","volume":"291","author":[{"given":"Qiushi","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva C.","family":"Vlaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon M.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erikjan","family":"Rijkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen A.A.","family":"Demmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold G.","family":"Vulto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niek P.","family":"van Til","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.W.M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jprot.2023.105037_bb0005","series-title":"The Metabolic and Molecular Basis for Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: Acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"issue":"9646","key":"10.1016\/j.jprot.2023.105037_bb0010","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0015","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.jprot.2023.105037_bb0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"Infantile-onset Pompe disease natural history study, a retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"Pt 3","key":"10.1016\/j.jprot.2023.105037_bb0025","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.jprot.2023.105037_bb0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe\u2019s disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jimd.12560","article-title":"Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism","volume":"46","author":"Canibano-Fraile","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056181","article-title":"Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease","volume":"8","author":"Taylor","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0045","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.3390\/ijms22062850","article-title":"Muscle proteomic profile before and after enzyme replacement therapy in late-onset Pompe disease","volume":"22","author":"Moriggi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0050","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajmg.c.31317","article-title":"Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten","volume":"160C","author":"Raben","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"4","key":"10.1016\/j.jprot.2023.105037_bb0060","first-page":"233","article-title":"Autophagic glycogenosis of late onset with mitochondrial abnormalities: light and electron microscopic observations","volume":"43","author":"Engel","year":"1968","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0065","first-page":"123","article-title":"Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study","volume":"46","author":"Lewandowska","year":"2008","journal-title":"Folia Neuropathol."},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","article-title":"Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease","volume":"11","author":"Lim","year":"2015","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0075","article-title":"Pompe disease: shared and unshared features of lysosomal storage disorders","volume":"3","author":"Lim","year":"2015","journal-title":"Rare Dis."},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0080","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van der Ploeg","year":"2017","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","volume":"6","author":"Ditters","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jprot.2023.105037_bb0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"issue":"19","key":"10.1016\/j.jprot.2023.105037_bb0100","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.jprot.2023.105037_bb0105","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","article-title":"Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience","volume":"33","author":"Chakrapani","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"8","key":"10.1016\/j.jprot.2023.105037_bb0115","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"issue":"8","key":"10.1016\/j.jprot.2023.105037_bb0125","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.jprot.2023.105037_bb0130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"issue":"19","key":"10.1016\/j.jprot.2023.105037_bb0135","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1212\/WNL.0b013e3182553c11","article-title":"Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy","volume":"78","author":"Ebbink","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jprot.2023.105037_bb0140","first-page":"98","article-title":"Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state","volume":"9","author":"Matsuoka","year":"2016","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0145","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10545-010-9209-0","article-title":"CRIM-negative infantile Pompe disease: 42-month treatment outcome","volume":"33","author":"Rohrbach","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0150","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"4","key":"10.1016\/j.jprot.2023.105037_bb0155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jgm.1305","article-title":"Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease","volume":"11","author":"Douillard-Guilloux","year":"2009","journal-title":"J. Gene Med."},{"issue":"26","key":"10.1016\/j.jprot.2023.105037_bb0160","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2009-11-252874","article-title":"Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype","volume":"115","author":"van Til","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jprot.2023.105037_bb0165","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2022.10.017","article-title":"Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease","volume":"27","author":"Dogan","year":"2022","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"key":"10.1016\/j.jprot.2023.105037_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2022.09.010","article-title":"IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy","volume":"27","author":"Liang","year":"2022","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"key":"10.1016\/j.jprot.2023.105037_bb0175","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2022.04.016","article-title":"Lentiviral gene therapy prevents anti-human acid \u03b1-glucosidase antibody formation in murine Pompe disease","volume":"25","author":"Liang","year":"2022","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"issue":"3","key":"10.1016\/j.jprot.2023.105037_bb0180","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0185","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1021\/acs.jproteome.5b00072","article-title":"Low-pH solid-phase amino labeling of complex peptide digests with TMTs improves peptide identification rates for multiplexed global Phosphopeptide analysis","volume":"14","author":"Bohm","year":"2015","journal-title":"J. Proteome Res."},{"issue":"9","key":"10.1016\/j.jprot.2023.105037_bb0190","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","article-title":"The Perseus computational platform for comprehensive analysis of (prote)omics data","volume":"13","author":"Tyanova","year":"2016","journal-title":"Nat. Methods"},{"issue":"9","key":"10.1016\/j.jprot.2023.105037_bb0195","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1101\/gr.772403","article-title":"PANTHER: a library of protein families and subfamilies indexed by function","volume":"13","author":"Thomas","year":"2003","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.jprot.2023.105037_bb0200","first-page":"523","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"19","key":"10.1016\/j.jprot.2023.105037_bb0205","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1093\/hmg\/ddr306","article-title":"Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways","volume":"20","author":"Palmieri","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"5939","key":"10.1016\/j.jprot.2023.105037_bb0210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.475","article-title":"Autophagy dysregulation in Danon disease","volume":"8","author":"Nascimbeni","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jprot.2023.105037_bb0220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front. Aging Neurosci."},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0225","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/mus.10381","article-title":"Morphological changes in muscle tissue of patients with infantile Pompe\u2019s disease receiving enzyme replacement therapy","volume":"27","author":"Winkel","year":"2003","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40478-018-0620-3","article-title":"Satellite cells maintain regenerative capacity but fail to repair disease-associated muscle damage in mice with Pompe disease","volume":"6","author":"Schaaf","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"12","key":"10.1016\/j.jprot.2023.105037_bb0235","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Investig."},{"issue":"5","key":"10.1016\/j.jprot.2023.105037_bb0240","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0245","doi-asserted-by":"crossref","first-page":"15089","DOI":"10.1038\/s41598-017-15352-2","article-title":"AAV-mediated transcription factor EB (TFEB) gene delivery ameliorates muscle pathology and function in the murine model of Pompe disease","volume":"7","author":"Gatto","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jprot.2023.105037_bb0250","doi-asserted-by":"crossref","first-page":"16054","DOI":"10.1038\/mtm.2016.54","article-title":"TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle","volume":"3","author":"Sato","year":"2016","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0255","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018267","article-title":"The actin cytoskeleton and actin-based motility","volume":"10","author":"Svitkina","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0260","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/15216540216037","article-title":"The role of troponins in muscle contraction","volume":"54","author":"Gomes","year":"2002","journal-title":"IUBMB Life"},{"issue":"10","key":"10.1016\/j.jprot.2023.105037_bb0265","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.3390\/ijms23105306","article-title":"The mechanisms of thin filament assembly and length regulation in muscles","volume":"23","author":"Szikora","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0270","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10974-020-09583-6","article-title":"Calsequestrin, a key protein in striated muscle health and disease","volume":"42","author":"Rossi","year":"2021","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.jprot.2023.105037_bb0275","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0065-3233(04)71004-9","article-title":"Regulation of muscle contraction by tropomyosin and troponin: how structure illuminates function","volume":"71","author":"Brown","year":"2005","journal-title":"Adv. Protein Chem."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13395-021-00279-0","article-title":"Protein profile of fiber types in human skeletal muscle: a single-fiber proteomics study","volume":"11","author":"Murgia","year":"2021","journal-title":"Skelet. Muscle"},{"issue":"Suppl. 1","key":"10.1016\/j.jprot.2023.105037_bb0285","first-page":"S42","article-title":"Autophagy in skeletal muscle: implications for Pompe disease","volume":"47 Suppl 1","author":"Shea","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.jprot.2023.105037_bb0290","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10545-012-9541-7","article-title":"Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype","volume":"36","author":"van den Berg","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.jprot.2023.105037_bb0295","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.nmd.2010.11.016","article-title":"A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers","volume":"21","author":"van den Berg","year":"2011","journal-title":"Neuromuscul. Disord."},{"issue":"1399","key":"10.1016\/j.jprot.2023.105037_bb0300","first-page":"965","article-title":"Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton","volume":"355","author":"Hall","year":"2000","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"issue":"5\u20136","key":"10.1016\/j.jprot.2023.105037_bb0305","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/21541248.2020.1822721","article-title":"New insights into RhoA\/rho-kinase signaling: a key regulator of vascular contraction","volume":"12","author":"Nunes","year":"2021","journal-title":"Small GTPases"},{"issue":"4","key":"10.1016\/j.jprot.2023.105037_bb0310","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/hmg\/ddp535","article-title":"Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease","volume":"19","author":"Douillard-Guilloux","year":"2010","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0315","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1079\/PNS2004331","article-title":"Regulation of fatty acid transport by fatty acid translocase\/CD36","volume":"63","author":"Bonen","year":"2004","journal-title":"Proc. Nutr. Soc."},{"issue":"38","key":"10.1016\/j.jprot.2023.105037_bb0320","doi-asserted-by":"crossref","first-page":"26761","DOI":"10.1074\/jbc.274.38.26761","article-title":"Muscle-specific overexpression of FAT\/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin","volume":"274","author":"Ibrahimi","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jprot.2023.105037_bb0325","first-page":"15","article-title":"Is membrane transport of FFA mediated by lipid, protein, or both? Mechanisms and regulation of protein-mediated cellular fatty acid uptake: molecular, biochemical, and physiological evidence","volume":"22","author":"Bonen","year":"2007","journal-title":"Physiology (Bethesda)"},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0330","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/jimd.12440","article-title":"The peroxisomal transporter ABCD3 plays a major role in hepatic dicarboxylic fatty acid metabolism and lipid homeostasis","volume":"44","author":"Ranea-Robles","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.jprot.2023.105037_bb0335","article-title":"The biological functions and regulatory mechanisms of fatty acid binding protein 5 in various diseases","volume":"10","author":"Xu","year":"2022","journal-title":"Front. Cell Develop. Biol."},{"issue":"8","key":"10.1016\/j.jprot.2023.105037_bb0340","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.7150\/thno.68611","article-title":"Annexin-A1 deficiency attenuates stress-induced tumor growth via fatty acid metabolism in mice: an integrated multiple omics analysis on the stress- microbiome-metabolite-epigenetic-oncology (SMMEO) axis","volume":"12","author":"Cui","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.jprot.2023.105037_bb0345","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/jimd.12344","article-title":"Combined proteomic and lipidomic studies in Pompe disease allow a better disease mechanism understanding","volume":"44","author":"Sidorina","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"12","key":"10.1016\/j.jprot.2023.105037_bb0350","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.3390\/ijms21124211","article-title":"Targeted Metabolomic analysis of a Mucopolysaccharidosis IIIB mouse model reveals an imbalance of branched-chain amino acid and fatty acid metabolism","volume":"21","author":"De Pasquale","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt 2","key":"10.1016\/j.jprot.2023.105037_bb0355","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/BJ20050236","article-title":"NPC1 late endosomes contain elevated levels of non-esterified (\u2019free\u2019) fatty acids and an abnormally glycosylated form of the NPC2 protein","volume":"390","author":"Chen","year":"2005","journal-title":"Biochem. J."},{"issue":"13","key":"10.1016\/j.jprot.2023.105037_bb0360","doi-asserted-by":"crossref","first-page":"292","DOI":"10.21037\/atm.2019.05.29","article-title":"Pompe disease: what are we missing?","volume":"7","author":"Schoser","year":"2019","journal-title":"Annal. Translat. Med."},{"issue":"9","key":"10.1016\/j.jprot.2023.105037_bb0365","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1462-5822.2007.00946.x","article-title":"Arrested maturation of Neisseria-containing phagosomes in the absence of the lysosome-associated membrane proteins, LAMP-1 and LAMP-2","volume":"9","author":"Binker","year":"2007","journal-title":"Cell. Microbiol."},{"issue":"2","key":"10.1016\/j.jprot.2023.105037_bb0370","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.emboj.7601511","article-title":"LAMP proteins are required for fusion of lysosomes with phagosomes","volume":"26","author":"Huynh","year":"2007","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.jprot.2023.105037_bb0375","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1078\/0171-9335-00092","article-title":"Disruption of the actin filament network affects delivery of endocytic contents marker to phagosomes with early endosome characteristics: the case of phagosomes with pathogenic mycobacteria","volume":"79","author":"Gu\u00e9rin","year":"2000","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.jprot.2023.105037_bb0380","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1749-6632.1975.tb19242.x","article-title":"Microtubules and the mobilization of lysosomes in phagocytizing human leukocytes","volume":"253","author":"Malawista","year":"1975","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"7","key":"10.1016\/j.jprot.2023.105037_bb0385","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1074\/jbc.271.7.3803","article-title":"Microtubule-associated protein-dependent binding of phagosomes to microtubules","volume":"271","author":"Blocker","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0390","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/s42003-022-03988-4","article-title":"Kinetics of phagosome maturation is coupled to their intracellular motility","volume":"5","author":"Yu","year":"2022","journal-title":"Commun. Biol."},{"issue":"10","key":"10.1016\/j.jprot.2023.105037_bb0395","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.220155","article-title":"Lysosomal positioning diseases: beyond substrate storage","volume":"12","author":"Scerra","year":"2022","journal-title":"Open Biol."},{"issue":"5","key":"10.1016\/j.jprot.2023.105037_bb0400","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nan.12214","article-title":"Impaired autophagy affects acid \u03b1-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II","volume":"41","author":"Nascimbeni","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"5","key":"10.1016\/j.jprot.2023.105037_bb0405","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4161\/auto.19469","article-title":"Autophagy in lysosomal storage disorders","volume":"8","author":"Lieberman","year":"2012","journal-title":"Autophagy"},{"issue":"24","key":"10.1016\/j.jprot.2023.105037_bb0410","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1093\/hmg\/ddn292","article-title":"Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease","volume":"17","author":"Raben","year":"2008","journal-title":"Hum. Mol. Genet."},{"issue":"33","key":"10.1016\/j.jprot.2023.105037_bb0415","doi-asserted-by":"crossref","first-page":"24131","DOI":"10.1074\/jbc.M702824200","article-title":"p62\/SQSTM1 binds directly to Atg8\/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy","volume":"282","author":"Pankiv","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jprot.2023.105037_bb0420","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00401-010-0732-8","article-title":"High-density areas on muscle CT in childhood-onset Pompe disease are caused by excess calcium accumulation","volume":"120","author":"Ishigaki","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.jprot.2023.105037_bb0425","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ymgme.2012.05.004","article-title":"Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients","volume":"106","author":"Palermo","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.jprot.2023.105037_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107526","article-title":"Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients","volume":"138","author":"Kinton","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.jprot.2023.105037_bb0435","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jprot.2023.105037_bb0440","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-017-0693-2","article-title":"A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease","volume":"12","author":"Byrne","year":"2017","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391923002269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391923002269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:17:03Z","timestamp":1761740223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391923002269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":88,"alternative-id":["S1874391923002269"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2023.105037","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2023.105037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105037"}}